Investments

In order to fulfill the promises we make to our business partners and patients, we are constantly looking for new opportunities for development and expansion.
The construction of the Research and Development Center is just the beginning of new possibilities in the implementation of innovative medicinal products.
See Synthaverse development directions.

Research and Development Center

The aim of the project is to introduce innovative products to the market on an international scale and to respond to the needs of patients.

Currently, our priority is the construction of the Research and Development Center and the production of innovative and highly specialized medicinal products. Thanks to the investment, we will be able to improve technologies related to vaccinology in the prevention of tuberculosis and immunology in the treatment of cancer.

The Research and Development Center will serve the development and market preparation of products that are innovative on an international scale and respond to customer needs, including a significantly improved BCG vaccine and an improved Onko BCG medicinal product.

The center is already at the final stage of construction, and the commissioning of the building is scheduled for December 2023.

Onko BCG® Manufacturing Facility

Our ambition is to launch the sale of the drug from the new line by 2016.

The Polish Agency for Enterprise Development, under the Smart Growth Operational Program 2014-2020, granted our organization a subsidy for the construction of a new plant in the amount of 60% of eligible costs.

The investment, equipped with a modern production line, will allow us to increase the production of the drug used in bladder BCG immunotherapy by about 300,000 packages per year. The production potential of this product will multiply.